In re application of:	Examiner: Vogel, Nancy S.
Kevin P. BAKER, et al.) Art Unit: 1636
Application Serial No. 10/006,856) Confirmation No: 8365
Filed: December 6, 2001	Attorney's Docket No. 39780-2830 P1C14
For: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME	Customer No. 35489)

EXPRESS MAIL LABEL NO. EV 765 985 918 US DATE MAILED: November 13, 2006

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP RCE

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with M.P.E.P. §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

11/16/2006 RFEKADU1 00000092 10006856

02 FC:1806

180.00 DA

	This st	atement qualifie	s under 37 C.F.R.	§1.97,	, subsection (b) because (check all that apply):	
٠		(1) than a	•		3 months of the application filing date and is of pplication under § 1.53(d)	ther
		(2)		within :	3 months of entry of a national stage	
		(3) merits	It is being filed	before	the mail date of the first Office Action on the	
		(4) of a re	•		the mailing of a first Office Action after the filinination under § 1.114.	ing
	filing d stage a action	late of a national s set forth in §1, on the merits, but	l application; (2) to 491 in an internat	three motional aping date	iled after the latest of: (1) three months beyond nonths beyond the date of entry of the national application; or (3) the mailing date of a first Offe of the earlier of a final office action under §1.	ice
		a certification	as specified in §1.	.97(e) is	s provided below; or	
	\boxtimes			-) is authorized below, enclosed, or included with her with this statement.	h
	37 C.F.R. $\S1.97(d)$. If this statement is being filed after the mailing date of the earlier of a final office action under $\S1.113$ or a notice of allowance under $\S1.311$, but before payment of the issue fee, then:					
	A.	a certification	as specified in §1.	97(e) is	s completed below; and	
٠	B.	a petition unde submitted here	•	(d) requ	uesting consideration of this statement is	
	C.	•	•	• • •	(1) is authorized below, enclosed, or included wher with this statement.	vith
\boxtimes	of \$180	0.00 and charge	any additional fee	es or cre	by authorized to charge the above-referenced fed edit any overpayment associated with this [1] (Attorney's Docket No. 39780-2830 P1C14	
				R	Respectfully submitted,	
Dated:	Novem	ber 13, 2006		By:	3: /2_ Barrie D. Greene (Reg. No. 46,740)	
HELLI	ER EHI	RMAN LLP				

275 Middlefield Road Menlo Park, California 94025-3506

Telephone: (650) 324-7000 Facsimile: (650) 324-0638

NOV 13 2006 PTO/SB/08 (2/92) Sheet 1 of 8 **Application Serial No. Form PTO-1449** Attorney's Docket No. 10/006,856 39780-2830 P1C14 Applicant(s) INFORMATION DISCLOSURE STATEME Kevin P. BAKER, et al. Filing Date: **Group Art Unit:** 1636 (use several sheets if necessary) December 6, 2001 U.S. PATENT DOCUMENTS **Filing Date** Document No. **Examiner** Ref. Class Subclass Date Name (if appropriate) Initials No. FOREIGN PATENT DOCUMENTS Document No. Name Class Subclass Translation Examiner Ref. Date Initials YES NO No. OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.) Ref. Title Examiner Initials No. Abe, N., et al., "An Increased High-Mobility Group A2 Expression Level is Associated with malignant Phenotype in 1. Pancreatic Exocrine Tissue," Br J Cancer - 89(11):2104-9 (2003) Abstract. Ando, M., et al., "Selective Apoptosis of Natural Killer-Cell Tumours by I-Asparaginase," Br J Haematol., - 130(6):860-8 2. (2005) Abstract. Aust, G., et al., "Human Thyroid Carcinoma Cell Lines and Normal Thyrocytes: Expression and Regulation of Matrix 3. Metalloproteinase Inhibitor-1 Messenger-RNA and Protein," Thyroid - 7(5):713-24 (1997) Abstract. Barnes, V.L., et al., " Expression of Embryonic Fibronectin Isoform EIIIA Parallels Alpha-Smooth Muscle Actin in 4. Maturing and Diseased Kidney," J Histochem Cytochem. - 47(6):787-98 (1999) Abstract. Bea, S., et al., "BMI-1 Gene Amplification and Overexpression in Hematological Malignancies Occur Mainly in Mantle 5. Cell Lymphonas," Cancer Res. - 61(6):2409-12 (2001) Abstract. Blaschke, V., et al., "Rapid Quantitation of Proinflammatory and Chemoattractant Cytokine Expression in Small Tissue Samples and Monocyte-Derived Dendritic Cells: Validation of a New Real-Time RT-PCR Technology," J Immunol 6. Methods. - 246(1-2):79-90 (2000) Abstract. Buckley, A.R., et al., "Butyrate-Induced Reversal of Dexamethasone Resistance in Autonomouse Rat Nb2 Lymphoma 7. Cells," *Apoptosis.* - <u>2(6)</u>:518-28 (1997) Abstract. Caberlotto, L. et al.,"Alterations in Neuropeptide Y Levels and Y1 Binding Sites in the Flinders Sensitive Line Rats, A 8. Genetic Animal Model of Depression," Neurosci Lett. - 265(3):191-4 (1999) Abstract. Caberlotto, L., et al., "Neurokinin 1 Receptor and Relative Abundance of the Short and Long Isoforms in the Human 9. Brain," Eur J Neurosci. - 17(9):1736-46 (2003) Abstract. Choi, D., et al., "Characterization of Cyclin D2 Expression in Human Endometrium," J Soc Gynecol Investig. - 9(1):41-6 10. (2002) Abstract. Couvelard, A., et al., "Human Chorionic Gonadotrophin Beta Expression in Malignant Barrett's Oesophagus," Virchows 11. Arch. - 445(3):279-84 (2004) Abstract. Dagenais, A., et al., "Downregulation of EnaC Activity and Expression by TNF-Alpha in Alveolar Epithelial Cells," Am J. 12. Physio Lung Cell Mol Physiol. - <u>286(2)</u>:L301-11 (2004) Abstract. De Boer, C.J., et al., "Involement of the CCNDI Gene in Hairy Cell Leukemia," Ann Oncol. - 7(3):251-6 (1996) Abstract. 13.

EXAMINER:	DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or no	t the citation conforms with MPEP 609. Draw a line through the citation if not in	

Debieve, F., et al., "Inhibin and Activin Production and Subunit Expression in Human Placental Cells Cultured in Vitro,"

Dong, Z., et al., "Expression of Membrane-Type Matrix Metalloproteinases 4, 5, and 6 in Mouse Corneas Infected with P.

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Mol Hum Reprod. - 6(8):743-9 (2000) Abstract.

Aeruginosa," Invest Opthalmol Vis Sci - 42(13):3223- (2001) Abstract.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2244473 v1

14.

15.

Form PTO-1449		Attorney's Docket No.	Application Serial No.	
		39780-2830 P1C14	10/006,856	
INFORMATION DISCLOSURE STATEMENT		Applicant(s)	•	
		Kevin P. BAK	ER, et al.	
		Filing Date:	Group Art Unit:	
(use se	veral sheets if necessary)	December 6, 2001	1636	
		DITHER DOCUMENTS hor, title, date, pertinent pages, etc.)		
16.		roliferative Activity in Colorectal Carcinomas ction (RT-PCR)," <i>Cancer Invest.</i> - 19(6):588-9	_	
17.	Dyer, J., et al., "Molecular Characteris Equine Vet J 34(4):349-58 (2002) Abs	ation of Carbohydrate Digestion and Absorp stract.	tion in Equine Small Intestine,"	
18.	Implications for Th Cell Lineage Comm	Cytokine Signaling Proteins are Differential nitment and Maintenance," <i>J Immunol.</i> - 168	3(7):3181-7 (2002) Abstract.	
19.	El-Ghrably, I.A., et al., "Intravitreal Invalidation Vitreoretinopathy," Br J Opthalmol	ading Cells Contribute to Vitreal Cytokine Mi <u>85(4)</u> :461-70 (2001) Abstract.	ilieu in Proliferative	
20.		utamatergic Receptors (AMPA and NMDA) a s after Axotomy," <i>Neuroscience - <u>136(1)</u>:147</i>		
- 21.	Forsberg, H., et al., "Altered Levels of Radic Res 24(6):451-9 (1996) Abstra	Scavenging Enzymes in Embryos Subjected ct.	I to a Diabetic Environment," <i>Fr</i> ee	
22.		e Estrogen Receptor by Growth Hormone ans," <i>Endocrinology</i> - <u>133(4)</u> :1548-54 (1993) Ab		
23.		Fu, K., et al., "Cyclin D1-Negative Mantle Cell Lymphoma: A Clinocopathologic Study Based on Gene Expression Profiling," Blood - 106(13):4315-21 (2005) Abstract.		
24.	Fuchs, A.R., et al., "Oxytocin Receptors in Bovine Cervix: Distrubution and Gene Expression During the Estrous Cycle," Biol Reprod 54(3):700-8 (1996) Abstract.			
25.	Furuta, J., et al., "Silencing of the Thro	Furuta, J., et al., "Silencing of the Thrombomodulin Gene in Human Malignant Melanoma," Melanoma Res 15(1):15-20		
26.	Futcher, B., et al., "A Sampling of the Yeast Proteome," Mol Cell Biol., - 19(11):7357-68 (1999) Abstract.			
27.		egulation of Cytochrome P450 Genes is Resp Among Patients with Cirrhosis," <i>Biochem Ph</i>	•	
28.	Giroux, M., et al., "Cyclooxygenase-2 l 165(7):3985-91 (2000) Abstract.	Expression in Macrophages: Modulation by I	Protein Kinase C-alpha," <i>J immunol.</i> -	
29.	Gnatenko, D.V., et al., "Transcript Prof Expression," Blood - 101(6):2285-93 (2	iling of Human Platelets Using Microarray at 003) Abstract.	nd Serial Analysis of Gene	
30.	Godbout, R., et al., "Overexpression o Biol Chem, - 273(33):21161-8 (1998) Ab	f DEAD Box Protein (DDX1) in Neuroblastom ostract.	a and Retinoblastoma Cell Lines," J	
31.	Goldenberg, R.C., et al., "Modulation of Endocrinol <u>177(2)</u> :327-35 (2003) Abs	of Gap Junction Mediated Intercellular Comr tract.	nunication in TM3 Leydig Cells," J	
32.	Golehiowski F et al "Everession Level of Libra Protein in Rat Tissues" Acta Riochim Pol - 50(4):1065-73 (2003)			
33.	Grem, J.L., et al., "Thymidine Kinase, Thymidylate Synthase, and Dihydropyrimidine Dehydrogenase Profiles of Cell Lines of the National Cancer Institute's Anticancer Drug Screen," Clin Cancer Res 7(4):999-1009 (2001) Abstract.			
34.	Grenback, E., et al., "Galanin Pituitary	Adenomas," <i>Regul Pept,</i> - <u>117(2)</u> :127-39 (200	04) Abstract.	
35.	Gromova, I., et al., "Protein Abundance and mRNA Levels of the Adipocyte-Type Fatty Acid Binding Protein Correlate in Non-Invasive and Invasive Bladder Transitional Cell Carcinomas," Int J. Oncol 13(2):379-83 (1998) Abstract.			
Guo, Y., et al., "The Pathogenic Role of Macrophage Migration Inhibitory Factor in Acute Respiratory Distress Syndrome," Zhinghua Jie He He Hu Xi Za Zhi - 25(6):337-40 (2002) Abstract.				

EXAMINER:	DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation consorted and not considered. Include a copy of this form with payt		

conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2244473 v1

Form PTO-1449		Form PTO-1449	Attorney's Docket No.	Application Serial No.
INFORMATION DISCLOSURE STATEMENT			39780-2830 P1C14	10/006,856
		N DISCLOSURE STATEMENT	Applicant(s)	
			Kevin P. BAK	
		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Filing Date:	Group Art Unit:
(1		eral sheets if necessary)	December 6, 2001	1636
	ж. ж. г	(including aut	hor, title, date, pertinent pages, etc.)	
	37.		and Activity of Organic Ion Transporters rochem Pharmacol - 69(6):993-9 (2005) Abstra	
			chrome P4501A1 in Teleosts: Sustained Indu	
	38.		odibenzofuran in the Marine Fish Stenotomi	us Chrysops," <i>Toxicol Appl</i>
		Pharmacol 127(2):187-98 (1994) Abs	S2 Gene in Breast Tissues Assessed by pS2	2-mRNA Analysis and nS2-Protein
	39. 	Radioimmunoassay," Breast Cancer R	Res Treat 24(1):71-4 (1992) Abstract.	<u> </u>
	40.	Hamilton, L.M., et al., "The role of the Severe Asthma," <i>Clin Exp Allergy</i> <u>33</u>	Epidermal Growth Factor Receptor in Sustai 8(2):233-40 (2003) Abstract.	ning Neutrophil Inflammation in
	41.	Hassett, C., et al., "Human Hepatic Mic Arch Biochem Biophys 337(2):275-8	crosomal Epoxide Hydrolase: Comparative A 3 (1997) Abstract.	Analysis of Polymorphic Expression,"
	42.		ation of Tissue Inhibitor of Metalloproteinas Cance, - 113(2):198-206 (2005) Abstract.	es 1 (TIMP-1) in Human Colorectal
	43.	Huang, Y.H., et al., "Tissue Plasminog Med Virol 70(4):610-6 (2003) Abstrac	en Activator Induced by Dengue Virus Infect t.	tion of Human Endothelial Cells," J
	44.		Expression in Ovarian Tumors: A Quantitativ	ve Study," <i>Mod Pathol.</i> - <u>5(3)</u> :250-6
	45.	Hui P et al "Real-time Quantitative RT-PCR of Cyclin D1 mRNA in Mantle Cell Lymphoma: Comparison with FISH and		
		Husain, I., et al., "Elevation of Topoiso	merase I Messenger RNA, Protein, and Cata	
	46.	Demonstration of Tumor-Type Specific (1994) Abstract.	city and Implications for Cancer Chemothera	apy," <i>Cancer Res</i> <u>54(2)</u> :539-46
	47.		uantification of Proliferation Marker pKi-67 i I Cancer Res Clin Oncol 130(12):749-56 (20	
	48.		agon Receptor Expression and Response in iol 281(4):C1396-402 (2001) Abstract.	Transfected Human Embryonic
	49.		Regulation of Acidic Fibroblast Growth Fact	or (aFGF) Expression in Bovine
	50.	Jaime, M., et al., "The p21 (Cip1) Prote	in, A Cyclin Inhibitor, Regulates the Levels a Hepatology - 35(5):1063-71 (2002) Abstract.	
	51.		zled Expression in renal Cell Carcinoma," To	
1 1	52.	Jungbluth, A.A., et al., "Immunohistoc Human Tissues," Int J. Cancer - 92(6):	hemical Analysis of NY-ESO-1 Antigen Expr	ession in Normal and Malignant
	Kalabis, G.M., et al., "Multidrug Resistance Phosphoglycoprotein (ABCB1) in the Mouse Placenta: Fetal Protection Biol Reprod 73(4):591-7 (2005) Abstract.			louse Placenta: Fetal Protection,"
	Kammaori, M., et al., "Expression of Human Telomerase Reverse Transcriptase Gene and Protein, and of Estrogen amd Progesterone Receptors, in Breast Tumors: Preliminary Data from Neo-Adjuvant Chemotherapy," Int J Oncol 27(5):1257-63 (2005) Abstract.			
	55.		quitin-Proteasome Pathway and Muscle Loss	s in Experimental Cancer Cachexi," Br
	5 6.		of Proteasome Subunits in Skeletal Muscle	of Cancer Patients with Weight Loss,"
EXAMINER:			DATE CONSIDERED:	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2244473 v1

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT		Attorney's Docket No.	Application Serial No.	
		39780-2830 P1C14 Applicant(s)	10/006,856	
INFORMATION DISCLOSURE STATEMENT			1	vin P. BAKER, et al.
			Filing Date:	Group Art Unit:
(use several sheets if necessary)			December 6, 2001	1636
(including auti			OTHER DOCUMENTS thor, title, date, pertinent pages, e	
	57.	Distinct mRNAs," J Biol Chem 279(24):25574-81 (2004) Abstract.	d –1beta in the Lung caused by Expression of
	58.	155:19-24 (1992) Abstract.		rian Cancer," Acta Obstet Gynecol Scand Suppl
	59.	Subtypes 1-5 and Correlation with Re 92(2):175-86 (2005) Abstract.	eceptor Protein Expression and To	ancer: Quantitative Analysis of mRNA for umor Pathology," <i>Breast Cancer Res. Treat.</i> -
	60.	Leukemia Cells," Proteomics - 5(4):89	94-906 (2005) Abstract.	ct of CpG-ODN on Human THP-1 Monocytic
	61.	Landmark, B.F., et al., "Cellular Local Protein Kinase in Rat Testis," <i>J Repre</i>	•	of the regulatory Subunits of cAMP-dependent stract.
	62.		•	sion in Colorectal Cancer by RT-PCR and July 1981 J Pathol 198(2):198-206 (2002) Abstract.
	63.	Legrand, O., et al., "Expression of the Peripheral Blood and Bone Marrow H	•	d Protein (MRP) mRNA and Protein in Normal ol 94(1):23-33 (1996) Abstract.
	64.	Lemstrom, K.B., et al., "Vascular End 105(21):2524-30 (2002) Abstract.	othelial Growth Factor Enhances	Cardiac Allograft Arteriosclerosis," Circulation -
	65.	Li, Z.B., et al., "Enhanced Expressions of Arachidonic Acid-Sensitive Tandem-Pore Domain Potassium Channels in Rat Experimental Acute Cerebral Ischemia," Biochem Biophys Res Commun 327(4):1163-9 (2005) Abstract.		
	66.			Protein 27," Invest Ophthalmol Vis Sci
	67.	\		ivator and Plasminogen Activator Inhibitor Type Biol 46(1):23-31 (2001) Abstract.
	68.		ration of Fixation on Quantitative	Reverse Transcription Polymerase Chain
·	69.		e Overexpressed in Pancreatic Ca	ncer and in Dysplastic Lesions in Chronic
	70.		ed and Inducible Expression of a	Yoked Hormone-Receptor Complex in HEK 293
	71.		os and Estrogen Receptor Gene E	xpression Pattern in the Rat Uterine Epithelium act.
	72.		and the mRNA for the NMDARI S	Subunit of the NMDA Receptor are Differentially
	73.	Mezzano, S.A., et al., "Overexpression Membranous Nephropathy," Kiney In	n of Chemokines, Fibrogenic Cyto	
	74.	Mingrone, G., et al., "Decreased Unco	oupling Protein Expression and In	tramyocytic Triglyceride Depletion in Formerly
	75.	Obese Subjects," Obes Res 11(5):632-40 (2003) Abstract. Miralles, C.P., et al., "Differential Expression of the Short and Long Forms of the Gamma 2 Subunit of the GABAA/benzodiazenine Recentors " Brain Res Mol Res 24(1-4):129-39 (1994) Abstract		
	76.	GABAA/benzodiazepine Receptors," <i>Brain Res Mol Res 24(1-4)</i> :129-39 (1994) Abstract. Mizrachi, D., et al.,"Follicle-stimulating Hormone Receptor and Its Messenger Ribonucleic Acid are Present in the Bovine Cervix and Can Regulate Cervical Prostanoid Synthesis," <i>Biol Reprod</i> 61(3):776-84 (1999) Abstract.		
	77.	Monaghan, P., et al., "The Alpha(v)be Constitutively on the Epithelial Cells"	•	
EVAMINED			DATE CONCIDERE	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2244473 v1

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT		Attorney's Docket No. 39780-2830 P1C14	Application Serial No. 10/006,856
		Applicant(s)	10/000,000
		Kevin P. BAK	ER, et al.
		Filing Date:	Group Art Unit:
(use sev	reral sheets if necessary)	December 6, 2001	1636
	(including aut	DIHER DOGUMENTS hor, title, date, pertinent/pages, etc.)	
78.	Montuori, N., et al., "Urokinase-Mediat Small Cell Lung Carcinoma," Int J Car	ed Posttranscriptional Regualtion of Urokina ocer - 105(3):353-60 (2003) Abstract.	
79.	MMP, MMP-2 and MMP-9 in Human Gli	al Growth Factor Expression Correlates with ioblastomas," <i>Int J Cancer</i> - 106(6):848-55 (2	003) Abstract.
80.		is a Mechanism for Loss of Expression of that as," Carcinogenesis - 22(10):1615-23 (2001)	
81.	Nuciforo, P.G., et al., "Molecular and In Hum Pathol 34(7):639-45 (2003) Abst	mmunohistochemical Analysis of HER2/neu tract.	Oncogene in Synovial Sarcoma,"
. 82.	Oberringer, M., et al., "Differential Exp Tissue," Biochem Biophys Res Comm	ression of Heat Shock Protein 70 in Well Heaun 214(3):1009-14 (1995) Abstract.	aling and Chronic Human Wound
83.		dy of Gene Copy Numbers, Transcripts, and onal Cell Carcincomas," <i>Mol Cell Proteomics</i>	
84.	· · · · · · · · · · · · · · · · · · ·	dy of Gene Copy Numbers, Transcripts, and onal Cell Carcinomas," <i>Molecular & Cellular</i>	
85.	Pachmann K et al "Expression of her-ahl mRNA in Individual Chronic Myelogenous Leukaemia Cells as determine		
86.	Pairon, J.C., et al., "Cell Localization and Regulation of Expression of Cytochrome P450 1A1 and 2B1 in Rat Lung a		
87.	Papotti, M., et al., "Correlative Immunohistochemical and Reverse Transcriptase Polymerase Chain Reaction Analysis		
88.		atostatin Receptor Types 1-5 in 81 Cases if (unohistochemical and Reverse-Transcriptase) -75 (2002) Abstract.	
89.		pression is an Indicator of Clinical Outcome pomethylation," <i>Clin Cancer Res.</i> - <u>11(16)</u> :58	
90.		owth Inhibitor Protein and Messenger Ribor land," <i>J Dairy Sci <u>75(6)</u>:1423-9 (1992)</i> Abst	
91. Preesman, A.H., et al., "T-Cell Receptor Hodgkin's Lymphomas," J Invest Derr			•
92.	Pullig, O., et al., "Matrilin-3 in Human Articular Cartilage: Increased Expression in Osteoarthritis," Osteoarthritis Cartilage - 10(4):253-63 (2002) Abstract. Rey, C., et al., "Up-regulation of Mitochondrial Peripheral Benzodiazepine Receptor Expression by Tumor Necrosis Factor Alpha in Testicular Leydig Cells. Possible Involvement in Cell Survival," Biochem Pharmacol 60(11):1636-46 (2000) Abstract. Rudlowski, C., et al., "GLUT1 Messenger RNA and Protein Induction Rrelates to the Malignant Transformation of Cervical Cancer," Am J. Clin Pathol 120(5):691-8 (2003) Abstract.		
93.			
94.			
95.		ribution of Laminin Alpha1 and Alpha2 Chai ch," <i>Exp Cell Res.</i> - <u>275(2)</u> :189-99 (2002) Abs	· · · · · · · · · · · · · · · · · · ·
96.	Sedelies, K.A., et al., "Discordant Regulation of the Biol Chem 279(25):26581-7 (2004) Ab	ulation of Granzyme H and Granzyme B Expostract.	ression in Human Lymphocytes," <i>J</i>

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conformance and not considered. Include a copy of this form with next of	lacksquare

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2244473 v1

		Form PTO-1449	Attorney's Docket No.	Application Serial No.
INFORMATION DISCLOSURE STATEMENT		<i>:</i>	39780-2830 P1C14	10/006,856
		N DISCLOSURE STATEMENT	Applicant(s)	
			Kevin P. BA	· · · · · · · · · · · · · · · · · · ·
(use several sheets if necessary)			Filing Date: December 6, 2001	Group Art Unit:
			OTHER DOCUMENTS thor, title, date, pertinent pages, etc.)	
			sion Parallels its mRNA level in normal and	Maligent B Cells," <i>Blood</i> -
	98.	Glucose Transporter Isoforms in North-1368(1):129-36 (1998) Abstract.	terminations of the Steady Transcript Levels mal Rat Tissues and the Malignant Tumor Co	ell Line AH130," Biochim Biophys Acta
	99.		nduced Activation of Activator Protein-1 is C Keratinocyte Cell Line HaCat," <i>Photochem I</i>	, -
	100.	Song, L., et al., "Rat Kidney Glutamyl Localization," Am J. Physiol 267(4 F	Aminopeptidase (aminopeptidase A): Molect 2):F546-57 (1994) Abstract.	ular Identity and Cellular
	101.		s Factor-Alpha Upregulates the Prostaglandi Amnion WISH Cells," <i>J Interferon Cytokine</i>	
	102.		ity of Potent Glucocorticoids: Relevance of 6 ppl Skin Physiol <u>16(3)</u> :143-50 (2003) Abstra	•
	103.	Splinter P.L. et al. "Specific Inhibition of AOP1 Water Channels in Isolated Rat Intrahenatic Bile Duct Units by Small		
	Stearns, M.E., et al., "Type IV Collagenase (M(r) 72,000) Expression in Human Prostate: Benign and Malignant Tissue," Cancer Res 53(4):878-83 (1993) Abstract.			state: Benign and Malignant Tissue,"
	105.	Stein R et al. "The Decompensated Detrusor III: Impact of Bladder Outlet Obstruction on Sarcoplasmic Endoplasmic		
	106.	Strickland, I., et al., "TNF-Alpha and IL-8 are Upregulated in the Epidermis of Normal Human Skin after UVB Exposure: Correlation with Nuetrophil Accumulation and E-Selectin Expression," J Invest Dermatol 108(5):763-8 (1997) Abstract.		
	107.		owth Factor Expression is Increased in Humaration," <i>Kidney Int.</i> - <u>57(4)</u> :1521-38 (2000) Al	
	108.	Takahashi, K., et al., "Adiposity Eleva Mice," J Biol. Chem 278(47):46654-6	ites Plasma MCP-1 Levels Leading to the Inc 60 (2003) Abstract.	reased CD11b-Positive Monocytes in
	109.	Takimoto, Y., et al., "Augmented Expr	ression of Neuronal Nitric Oxide Synthase in Iyocardial Infarction in Rats," <i>Circulation</i> - 1	
	110.	Telek, G., et al., "Differential Upregula	ation of Cellular Adhesion Molecules at the Sturg Res 96(1):56-67 (2001) Abstract.	· · · · · · · · · · · · · · · · · · ·
	111.	Timchenko, L., et al., "Myotonic Dystr 6(1):13-9 (1995) Abstract.	ophy: An Unstable CTG Repeat in a Protein	Kinase Gene," Semin Cell Biol
	112.	Torronen, R., et al., "Induction of Clas Chemicals," Chem Biol. Interact 83(ss 3 Aldehyde Dehydrogenase in the Mouse 2):107-19 (1992) Abstract.	Hepatoma Cell Line Hepa-1 by Various
	113.	Illimannova V. et al. "Relationship Between Cyclin D1 and n21 (Waf1/Cip1) During Differentiation of Human Myelo		
	114.	Van Beers, E.H., et al., "Intestinal Carbamoyl Phosphate Synthase I in Human and Rat. Expression during Development		
	115.		of Deoxycytidine Kinase in Leukaemic Cells iver," <i>Eur J Cancer</i> - <u>39(5)</u> :691-7 (2003) Abst	•
	116.	Waldherr, R., et al., "Expression of Cy <u>7(4)</u> :471-8 (1993) Abstract.	tokines and Growth Factors in Human Glom	nerulonephritides," <i>Pediatr Nephrol</i>
EXAMINER:			DATE CONSIDERED:	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in
conformance and not considered. Include a copy of this form with next communication to applicant.
*If an actorick is placed heside the reference number, a convict not provided because the reference was proviously cited by or submitted

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2244473 v1

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT		Attorney's Docket No.	Application Serial No.	
		39780-2830 P1C14 Applicant(s)	10/006,856	
INFORMATIO	M DISCLOSURE STATEMENT	Kevin P. BAKER, et al.		
		Filing Date:	Group Art Unit:	
(use sev	veral sheets if necessary)	December 6, 2001	1636	
		OTHER DOCUMENTS		
		<i>hor, title, date, pertinent pages, etc.)</i> formation of the Human Endometrium is ass	ociated with Overexpression of	
117.	•	in," <i>Cancer Res.</i> - <u>55(5)</u> :1168-75 (1995) Abst		
118.	Expression: An Immunohistochemica	luman Soft Tissue Tumors Correlates with P I and in Situ Hybridization Study," <i>Cancer R</i>	es <u>54(2)</u> :560-4 (1994) Abstract.	
119.	and Corresponding Prostatectomy Sp	rins and Catenins in Paired Tumor and Non- ecimens," <i>Urol Res.</i> - <u>28(5)</u> :308-15 (2000) Ab	stract.	
420		of Prostate-Specific Antigen Expression by F	——————————————————————————————————————	
120.	Gene in LNCaP Cells," Cancer Res 5	en Receptor and Steroid Receptor-binding C (7/4):714-9 (1997) Abstract.	onsensus in the Promoter of the PSA	
121.	<u> </u>	Calcyclin in Human Melanocytic Lesions,"	Cancer Res <u>53(24)</u> :6061-6 (1993)	
122.	Williams, E.T., et al., "Estrogen Regula 311(2):728-35 (2004) Abstract.	ation of the Cytochrome P450 3A Subfamily	in Humans," J Pharmacol Exp Ther.	
123.	Wojtaszek, P.A., et al., "Severely Decre Responsiveness" Oncogene - 8(3):75	eased MARCKS Expression Correlates with 5-60 (1993) Abstract.	Ras Reversion but not with Mitogenic	
124.	Zhong, W., et al., "Expression of Supe Radic Biol Med 27(11-12):1334-45 (19	roxide Dismutases, Catalase, and Glutathio 999) Abstract.	ne Peroxidase in Glioma Cells," <i>Free</i>	
125.	Xi, L., et al., "Expression of Human Te Zhonghua Fu Chan Ke Za Zhi - 40(6):4	Iomerase Reverse Transcriptase in Cervix C 07-10 (2005) Abstract.	ancer and its Significance,"	
	T =			
126.		f the Cell (3rd ed. 1994) Cell 3rd at 453 Figure		
127.	Cell 4th Cell 4th at 364 Cell 4th at 379	f the Cell (4 rd ed.) In Cell 4 th , Figure 6-3 on pa		
128.		oma Cell Lines and Normal Thyrocytes: Exp Metalloproteinase Inhibitor-` Messenger-Ri	•	
129.	Beà, S., et al., "BMI-1 Gene Amplificati Cell Lymphomas," Cancer Research -	on and Overexpression in Hematological Ma 61:2409-2412 (2001)	alignancies Occur Mainly in Mantle	
130.	Beer, et al, "Gene-expression profiles 98(6):816-824 (2002)	predict survival of patients with lung adeno-	carcinoma," Nature Biomedicine -	
131. Frohnert, B.I. et al., "Identification of a transport protein gene," J. Biol. Chem.		functional peroxisome proliferator-responsive 274:3970-3977 (1999).	e element in the murine fatty acid	
132.	Futcher, B., et al., "A Sampling of the	Yeast Proteome," Molecular and Cellular Bio	ology - <u>19(11)</u> :7357-7368 (1999)	
133.	Giovanni, P. N., et al., "Molecular and I Human Pathology - 34(7):639-645 (200	mmunohistochemical Analysis of HER2/neu	Oncogene in Synovial Sarcoma,"	
134.	Gnatenko, D.V., et al., "Transcript Prof Expression," Blood - 101(6):2285-2293	iling of Human Platelets Using Microarray at (2003)	nd Serial Analysis of Gene	
135.	Greenbaum, D., et al., "Analysis of mR of the Enrichment of Features in the C (2002)	NA Expression and Protein Abundance Data ellular Population of Proteins and Transcrip	ts," <i>Bioinformaticsl</i> - <u>18(4)</u> :585-496	
136.	· ·	y and mRNA Levels of the Adipocyte-Type F ansitional Cell Carcinomas," <i>International Jo</i>	=	

EXAMINER:	DATE CONSIDERED:	/		
		,′		
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in				
conformance and not considered. Include a copy of this form with next of	communication to applicant.			
*If an asterisk is placed beside the reference number, a copy is not provide	ded because the reference was previously cited by or submitted t	to the		

PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2244473 v1

		Attorney's Docket No. 39780-2830 P1C14	Application Serial No. 10/006,856		
			10/000,000		
INFORMATIO	ON DISCLOSURE STATEMENT	1	Applicant(s) Kevin P. BAKER, et al.		
		Filing Date:	Group Art Unit:		
///	veral cheets if necessary)	December 6, 2001	1636		
use se	veral sheets if necessary)	December 0, 2001	1000		
	(1998)	• • • • • • • • • • • • • • • • • • •			
	(including au	OTHER DOCUMENTS thor, title, date, pertinent pages, et	(c)		
Hähnel, E., et al., "Expression of the pS2 Gene in Breast Tissues Assessed by pS2-mF					
107.	Radioimmunoassay," Breast Cancer	adioimmunoassay," Breast Cancer Research and Treatment - 24:71-74 (1992)			
138.	Hirsch, F.R., et al., "Early Detection of Lung Cancer: Clinical Perspectives of Recent Advances in Biology and Radiology," Clinical Cancer Research - 7:5-22 (2001)				
139.	Holten-Andersen, M.D., et al., "Localization of Tissue Inhibitor of Metalloproteinases 1 (TIMP-1) in Human Colorectal Adenoma and Adenocarcinoma," <i>Int. J. Cancerl</i> - 113:198-206 (2005)				
140.	DE 10 10 10 10 10 10 10 10 10 10 10 10 10				
141.	Kammori, M., et al., "Expression of He Progesterone Receptors, in Breast To of Oncology - 27(5) (2005)	uman Telomerase Reverse Transcumors: Preliminary Data from Neo	riptase Gene and Protein, and of Estrogen and -Adjuvant Chemotherapy", International <i>Journal</i>		
142.	Kuo, C.C., et al., "A Transcriptomic and Leukemia Cells," Proteomics - 5:894-		t of CpG-ODN on Human THP-1 Monocytic		
143.	1 D O M (4007 O M)				
144.	Martin, G. et al., "Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA syntetase of the protein and acyl-CoA syntetase of the fatty acid transport protein and acyl-CoA syntetase of the fatty acid transport protein and acyl-CoA syntetase of the fatty acid transport protein and acyl-CoA syntetase of the fatty acid transport protein and acyl-CoA syntetase of the fatty acid transport protein and acyl-CoA syntetase of the fatty acid transport protein and acyl-CoA syntetase of the fatty acid transport protein and acyl-CoA syntetase of the fatty acid transport protein and acyl-CoA syntetase of the fatty acid transport protein and acyl-CoA syntetase of the fatty acid transport protein and acyl-CoA syntetase of the fatty acid transport protein and acyl-CoA syntetase of the fatty acid transport protein and acyl-CoA syntetase of the fatty acid transport protein and acyl-CoA syntetase of the fatty acid transport protein and acyl-CoA syntetase of the fatty acid transport protein acid transp				
145.	979 (2002)				
146.	Munaut, C., et al., "Vascular Endothelial Growth Factor Expression Correlates With Matrix Metalloproteinases MT1-NMP, MNP-2 and NMP-9 in Human Glioblastomas," Int. J. Cancer - 106:848-855 (2003)				
147.	Maruyama H. et al. "Id-1 and Id-2 are Overexpressed in Pancreatic Cancer and in Dysplastic Lesions in Chronic				
148.	of Somatostatin Receptor Type 2 in N (2000)	leuroendocrine Tumors of the Lun	scriptase Polymerase Chain Reaction Analysis g," <i>Diagnostic Molecular Pathology</i> - <u>9(1)</u> :47-57		
149.	Lactoferrin Messenger RNA and Prot	ein," <i>Cancer Research</i> - <u>55(5)</u> :1168			
150.	and Corresponding Prostatectomy S	pecimens," <i>Urol Resl</i> - <u>28</u> :308-315			
151.	Zhigang, Z., et al., "Prostate Stem Ce Role in Prostate Carinogenesis and P	II Antigen (PSCA) Express in Huma Progession of Prostate Cancer," <i>W</i>	an Prostate Cancer Tissues and its Potential orld Journal of Surgical Oncology - 2-13 (2004)		
		·····			
		•			

EXAMINER:	DATE CONSIDERED:	
		1
EXAMINER: Initial if citation considered, whether or not the citation con	forms with MPEP 609. Draw a line through the citation if not in	

conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filling date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2244473 v1